




# Challenges in Identifying Food Components Responsible for Health Effects in Whole Foods

Elizabeth Jeffery, Bioactive Food  
Components March 24-25, 2005



ILLINOIS  
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN

**Our single greatest need in the field of BFC study is information: we need a solid scientific basis of knowledge about the food and the individuals who will consume the food**



# **Q** Are Cranberries an effective functional food?

**Is protection from urinary infection an old wives tale or alternative medicine ?**

**Heath Family: *Ericaceae***

- *cranberries,*  
*blueberries,*  
*huckleberries,*  
*bilberries***



**A** Gold standard response: Clinical trials can effectively persuade us of efficacy; history of use assumes safety.

# Clinical Trials of Cranberries in Prevention of Urinary Tract Infection

Reference	Patient Group	<i>n</i>	Trial Design	Cranberry Juice Dose	Outcome
Dignam <i>et.al.</i> (1977)[27]	Elderly men and women	538	Historical Comparisons	6 capsules or 220 ml/day	Fewer UTIs (P=0.001)
Avon <i>et.al.</i> (1994)[25]	Elderly women	153	Placebo-controlled	300ml/day	Reduced bacteriuria (P=0.004)
Haverkorn and Mandigers (1994)[30]	Elderly men and women	7	Crossover (not blinded)	15 ml twice daily	Fewer UTIs (P=0.004)
Walker <i>et.al.</i> (1997)[28]	Middle-aged women	10	Crossover (double-blind)	400 mg capsules/day	Fewer UTIs (P<0.005)

# Fruits, Vegetables & Cancer Prevention: Epidemiology is undecided

---

<u>Variety or Category</u>	<u>% Positive</u>
<b>Vegetables</b>	<b>80% (59/74)</b>
<b>Fruits</b>	<b>64% (36/56)</b>
<b>Raw vegetables</b>	<b>87% (40/46)</b>
<b>Cruciferous Vegetables</b>	<b>69% (38/55)</b>
<b>Allium Vegetables</b>	<b>77% (27/35)</b>
<b>Green vegetables</b>	<b>77% (68/88)</b>
<b>Carrots</b>	<b>81% (59/73)</b>
<b>Tomatoes</b>	<b>71% (36/51)</b>
<b>Citrus Fruit</b>	<b>66% (27/41)</b>

**The 1997 World Cancer Research Fund and the American Institute for Cancer Research (WCRF/AICR) report:  
Food, Nutrition and the Prevention of Cancer: a global perspective, p442. by John D Potter and other panel members**

**SAFE  
EFFECTIVE  
BFC**

The diagram consists of three main components. At the top center is a light green, seven-pointed star with a black outline. Inside this star, the words 'SAFE', 'EFFECTIVE', and 'BFC' are stacked vertically in bold, black, sans-serif capital letters. Below the star are two rectangular boxes. The box on the left is light green with a dark green border and contains the text 'BFC i.d. Formulation' in bold, black, sans-serif font. The box on the right is light blue with a dark blue border and contains the text 'Bioavailability Biomarkers' in bold, black, sans-serif font. The star is positioned such that it appears to be the result or goal of the information provided in the two boxes below it.

**BFC i.d.  
Formulation**

**Bioavailability  
Biomarkers**

## **BFC i.d. Formulation**

**What is/are the active component(s), the food ?  
(garlic; olive oil; full Latin name if botanical)**

**Do multiple components have different roles,  
affecting different endpoints ?**

**Do components (active and/or inactive) interact ?  
(matrix effects; synergism between components)**

**Some foods contain multiple, differently acting, bioactive components**

**Tea contains not only polyphenolic anticarcinogens such as Epigallocatechin-3-gallate, but 2 – 10 mM L-theanine also.**


**Alkylamines have been found to boost the immune system.**

**Kamath et al, 2003. PNAS 100:6009-6014**






# WHOLE FOOD



**ACTIVITY (FOOD) =?= ACTIVITIES ( $\Sigma$  KNOWN BFCs)**

# Synergism in bioactivity

## Quinone Reductase Activity



Mean  $\pm$  SE, n=4 male F344 rats; ( $p \leq 0.05$ , ANOVA & LSD)

Dose: 50 mg/kg rat crambene; 56 mg/kg rat Indole-3-carbinol

# **Bioavailability Biomarkers**


**Biomarkers of exposure/ bioavailability  
(dietary intake measures;  
systemic levels; pharmacokinetic studies)**

**Biomarkers of efficacy  
(endpoint choices; validation)**

**Biomarkers of unexpected/ unwanted effects  
(the Vioxx factor; safety profile )**


**Biomarkers of Risk  
(genotyping, environment)**

# Glucoraphanin Hydrolysis




Myrosinase  
(Crushing) or gut bacteria

Unstable  
Intermediate




10-15%



Sulforaphane

85-90%



Sulforaphane Nitrile  
INACTIVE!

Matusheski et al, 2001

# **Bioavailability Biomarkers**

**Biomarkers of exposure  
(dietary intake measures)**

**Bioavailability:  
systemic levels and pharmacokinetics  
(lycopene, sulforaphane)**

**Biomarkers of efficacy  
(endpoint choices; validation)**

**Biomarkers of unexpected/ unwanted effects  
(the Vioxx factor; safety profile )**

**Biomarkers of Risk  
(genotyping, environment)**


# “Antioxidants per serving”

What does this mean ?

Dark Chocolate	951 mg/40 g
Milk Chocolate	394 mg/40 g
Hot Chocolate	45 mg/240 mL


Black Tea	943 mg/240 mL
Red Wine	431 mg/240 mL

# The Oxygen Radical Absorbance Capacity (ORAC) correlates with estimate of total polyphenols



**Not validated for any bioassay of antioxidant activity**

# ORAC showed poor correlation with a cellular measure of antioxidant activity



**22 broccoli genotypes; extracts analyzed by ORAC and by a dichlorofluorescein measure of ROS quenching by extracts in HepG2 cells.**



# **Bioavailability Biomarkers**

**Biomarkers of exposure**  
**(dietary intake measures)**

**Bioavailability:**  
**systemic levels and pharmacokinetics**  
**(lycopene, sulforaphane)**

**Biomarkers of efficacy**  
**(endpoint choices; validation)**

**Biomarkers of unexpected/ unwanted effects**  
**(the Vioxx factor; safety profile )**

**Biomarkers of Risk**  
**(genotyping, environment)**

# Effective Dose

```
graph BT; PG[Plant Genetics] --> ED[Effective Dose]; GE[Growing Environment] --> ED; BFC[BFC i.d. Formulation] --> ED; BB[Bioavailability Biomarkers] --> ED; P[Phenotype] --> ED;
```

*Plant  
Genetics*


*Growing  
Environment*

**BFC i.d.  
Formulation**

**Bioavailability  
Biomarkers**

*Phenotype*

**Food  
Variability**



**BFC i.d.  
Formulation**

**SAFE  
EFFECTIVE  
BFC**

**Human  
Variability**



**Bioavailability  
Biomarkers**

## Food variability

### 2003 USDA Nutritional Data for RAW BROCCOLI (abridged): Mean value per 100.00 grams edible part

Name	Unit	Amount	%RDA
Food energy	kcal :	28.00	1.0%
Protein	g :	2.98	4.7%
Total lipid (fat)	g :	0.35	0.4%
Carbohydrate	g :	5.240	1.1%
Total saturated fat	g :	0.05	0.2%
Cholesterol	mg :	0.00	0.0%
Total dietary fiber	g :	3.00	12.0%
Vitamin A	IU :	1542.00	15.4%
Ascorbic acid	mg :	93.20	155.3%

## Food variability


### 2005 and 2003 USDA Nutritional Data for RAW BROCCOLI (abridged): Mean value per 100.00 grams edible part

Name	Unit	Amount 2003	Amount 2005	#data points	S.E.
Food energy	kcal:	28.00	28.00	1	
Protein	g :	2.98	2.98	22	.11
Total lipid (fat)	g :	0.35	0.35	22	.03
Carbohydrate	g :	5.24	5.24	1	
Total saturated fat	g :	0.05	0.05	1	
Cholesterol	mg :	0	0	1	
Total dietary fiber	g :	3.0	-		
Vitamin A	IU :	1542	3000	1	
Ascorbic acid	mg :	93.2	93.2	15	2

# Mean Vitamin Levels in 50 Broccoli Genotypes (mg/ 100 g fresh weight)

<b><math>\beta</math>-carotene</b>	<b>0.89</b>
<b>range</b>	<b>0.37 - 2.42</b>
<b><math>\alpha</math> -tocopherol</b>	<b>1.62</b>
<b>range</b>	<b>0.46 - 4.29</b>
<b>Ascorbate</b>	<b>74.7</b>
<b>range</b>	<b>54.0 - 119.8</b>

# Carotenoid content of Broccoli




Means, 22 different broccoli genotypes ( $\mu\text{mol}/100\text{g DW}$ )

Eberhardt et al, in preparation

# Variability due to Genotype, Environment or GxE

Lutein




G: 71.2%\*

E: <1.0%

GxE: 27.4%\*


$\beta$ -Carotene



G: 50.0%\*

E: 13.9%

GxE: 30.6%\*



\*  $p < 0.05$


10 broccoli genotypes, 4 environments

Kobira et al, unpublished




# Stability Analysis of GxE variability in 6 genotypes: 2 genotypes accounted for most GxE variability

## Lutein




## $\beta$ -Carotene



## Conclusions:

- Significant proportion of variance ( $P < 0.05$ ) due to genotype : can breed for higher levels
- Significant proportion of GxE variance ( $P < 0.05$ ) due to GxE : need choice of stable varieties as parents in a breeding program

# Glucosinolate variation among 50 broccoli varieties; one season



Kushad et al, 1999

## Food variability

**MARKET STAGE  
BROCCOLI :**

**Broad variation in content  
of glucoraphanin**

**3-DAY SPROUTS**



**single variety on the  
market, less variation**


**EXTRACT, AS FREEZE-  
FRIED POWDER or TEA**



**Least variation: Each lot  
can be analyzed**

**For clinical studies, variability can best be overcome by using juices,  
extracts or freeze-dried preparations.**

**Food  
Variability**




**BFC i.d.  
Formulation**

**SAFE  
EFFECTIVE  
BFC**

**Human  
Variability**




**Bioavailability  
Biomarkers**






# Epidemiology of Dietary Cancer Prevention : Fruit and Vegetables

## Case-Control Studies




## Cohort Studies



# Crucifers Lower Risk for Lung Cancer More Effectively in those at high risk


	Relative risk
Crucifers/ non-smokers	0.70 (ns)
Crucifers/smokers	0.31 ( $p < 0.05$ )

# Breast Cancer Risk is lowered by dietary Crucifers in those with a GSTT1 Null Phenotype






# Synthesis of phosphatidylcholine




**Metabolic redundancy: most pathways have built-in redundancy: here there are two paths for phosphatidyl choline formation**

An example of enhanced choline requirement in a few individuals, to meet a metabolic need (choline acting as an essential nutrient) – choline is not acting as a BFC

# Synthesis of phosphatidylcholine



**Food  
Variability**



**BFC i.d.  
Formulation**

**SAFE  
EFFECTIVE  
BFC**

**Human  
Variability**



**Bioavailability  
Biomarkers**

<b>PRODUCT</b>	<b>SAFETY</b>	<b>EFFICACY</b>
----------------	---------------	-----------------

<b>Food</b>	<b>history of use</b>	<b>animal/ clinical</b>
-------------	-----------------------	-------------------------

<b>Drug</b>	<b>pre/clinical/post</b>	<b>pre/clinical</b>
-------------	--------------------------	---------------------

## PRODUCT

## SAFETY


## EFFICACY

**Food**

**history of use**

**animal/ clinical  
Epi &  
feeding**

→ **Dietary supplement  
semipurified BFC**



→ **Dietary supplement  
purified BFC**

## PRODUCT

## SAFETY

## EFFICACY

Food


history of use

animal/ clinical


→ Dietary supplement/  
semipurified

→ Dietary supplement/  
purified

→ Drug



pre/clinical/post



pre/clinical

If BFC are purified, for supplements or fortification of foods, do we need to provide more safety (or efficacy) evaluation prior to use ?

# PRODUCT

# SAFETY

# EFFICACY

Food

→ Dietary supplement/  
semipurified

→ Dietary supplement/  
purified

→ Drug

history of use



?



★  
Pre: acute, chronic  
Clinical: acute  
Post: AER

animal/ clinical



?



★  
Pre: in vitro, animals  
Clinical: IND; trials

For drugs, we require acute and chronic testing  
preclinical, acute clinical evaluation of safety and  
post-market adverse event reporting

# PRODUCT

# SAFETY

# EFFICACY

Food

history of use

animal/ clinical

→ Dietary supplement/  
semipurified

→ Dietary supplement/  
purified

→ Drug



?



★  
Pre: acute, chronic  
Clinical: acute  
Post: AER



?



★  
Pre: in vitro, animals  
Clinical: IND; trials



Do we need to develop a safety profile in  
animal studies, that can act as an early  
warning system for safety of purified BFC ?